Quantcast
Last updated on April 18, 2014 at 10:22 EDT

Latest Adeona Stories

2012-02-09 14:32:00

ANN ARBOR, Mich., Feb. 9, 2012 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN), a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses, announced today that Jeff Riley, the Company's Chief Executive Officer and Chairman, will be the featured presenter at the upcoming Harvard Investors Group forum. Mr. Riley will provide an overview of the Company's synthetic biologics program, its collaboration with Intrexon Corporation...

2012-02-07 05:30:00

ANN ARBOR, Mich., Feb. 7, 2012 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN), a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses, announced today that C. Evan Ballantyne has joined the Company as Chief Financial Officer. In this position, Mr. Ballantyne will be responsible for all aspects of the Company's financial, accounting and investor relations functions. From 2006 until its acquisition in...

2012-02-06 05:30:00

ANN ARBOR, Mich., Feb. 6, 2012 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN), a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses, announced today executive management transitions and Board of Director appointments to strengthen and expand the Company's leadership, as follows: Jeff Riley, a member of the Adeona Board of Directors since March 2010 and Chairman of the Board since November 2011, was appointed as...

2011-11-21 05:30:00

ANN ARBOR, Mich., and GERMANTOWN, Md., Nov. 21, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN), a developer of innovative disease-modifying medicines for serious illnesses, and the Human Therapeutics Division of Intrexon Corporation, a synthetic biology company that utilizes its proprietary technologies to provide control over cellular function, announced today the formation of a global exclusive channel collaboration through which Adeona intends to develop and...

2011-11-09 13:00:00

ANN ARBOR, Mich., Nov. 9, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (AMEX: AEN), a developer of innovative medicines for serious central nervous system diseases, announced today that it will hold its third quarter 2011 investor conference call on Monday, November 14, 2011, at 2:00pm EST. James S. Kuo, M.D., M.B.A., Adeona's Chief Executive Officer, will provide an overview of the Company's multiple sclerosis (MS), ALS and Alzheimer's clinical development programs and...

2011-11-07 08:00:00

ANN ARBOR, Mich., Nov. 7, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN), announced today that it has executed an agreement with F&F Foods of Chicago, Illinois, to provide commercial-scale manufacturing of wellZin(TM), the Company's oral zinc lozenge to reduce the duration and symptoms of the common cold. Adeona is planning to commercialize wellZin, a lozenge that contains 13.3 mg of zinc acetate, based on formulations clinically tested by Ananda S. Prasad, M.D.,...

2011-11-02 08:01:00

ANN ARBOR, Mich., Nov. 2, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN), is pleased to announce the appointment of Jeff Riley, to serve as its independent, non-executive Chairman of the Board. Mr. Riley has served on the Company's Board of Directors since March of 2010, and will continue to serve on the Audit and Nominations Committees. James S. Kuo, M.D., M.B.A., will continue to serve as Adeona's Chief Executive Officer, President and as a member of the Board. Mr....

2011-10-27 08:15:00

ANN ARBOR, Mich., Oct. 27, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN), announced today that Chardan Capital Markets initiated independent equity research coverage of the Company with a "Buy" rating and a 12-month price target of $1.00 per share. The report, issued yesterday, was authored by Keay Nakae, Senior Healthcare Analyst at Chardan. Headquartered in New York, Chardan is an investment banking and institutional brokerage firm with a focus on micro, small and...

2011-10-05 11:29:00

ANN ARBOR, Mich., Oct. 5, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN), a developer of innovative medicines for serious central nervous system diseases, announced today that James S. Kuo, M.D., M.B.A., the Company's Chief Executive Officer and Chairman, will provide a brief update on its Alzheimer's program at the NYC Medtech Forum. Adeona will be one of four featured companies at the invitation-only event on Tuesday evening, October 11, 2011, at the offices of Kaye...

2011-08-25 07:58:00

ANN ARBOR, Mich., Aug. 25, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN) announced today that it has appointed George A. Eby, a researcher who has conducted multiple clinical studies of zinc lozenges for the common cold, as a member of its Scientific Advisory Board. Mr. Eby is a pioneer in the development of zinc lozenges as a treatment for the common cold. He has devoted more than 30 years to the study of zinc and is the executive director of the George Eby Research...